{
  "doc_id": "8_glucosecontrol__7ec575",
  "original_filename": "8_GlucoseControl.pdf",
  "md_path": "data/parsed/8_GlucoseControl/8_GlucoseControl.md",
  "rmd_path": "data/parsed/8_GlucoseControl/8_GlucoseControl.rmd",
  "blocks": [
    {
      "type": "heading",
      "level": 1,
      "section": "NUTRITION SUPPORT CERTIFICATE",
      "line": 0
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Glucose Control in Nutrition Support",
      "line": 2
    },
    {
      "type": "image",
      "section": "Glucose Control in Nutrition Support",
      "line": 4,
      "content": "![img-0.jpeg](images/9c01a79eee8ab186.png)"
    },
    {
      "type": "text",
      "section": "Glucose Control in Nutrition Support",
      "line": 6,
      "preview": "Planned by the American Society of Health-System Pharmacists (ASHP) in collaboration with the Americ"
    },
    {
      "type": "text",
      "section": "Glucose Control in Nutrition Support",
      "line": 7,
      "preview": "(c)2022 American Society of Health-System Pharmacists, Inc. All rights reserved."
    },
    {
      "type": "text",
      "section": "Glucose Control in Nutrition Support",
      "line": 9,
      "preview": "No part of this publication may be reproduced or transmitted in any form or by any means, electronic"
    },
    {
      "type": "text",
      "section": "Glucose Control in Nutrition Support",
      "line": 11,
      "preview": "--- page 1 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "NUTRITION SUPPORT COMPLICATIONS: GLUCOSE CONTROL IN NUTRITION SUPPORT",
      "line": 13
    },
    {
      "type": "text",
      "section": "NUTRITION SUPPORT COMPLICATIONS: GLUCOSE CONTROL IN NUTRITION SUPPORT",
      "line": 15,
      "preview": "Jay M Mirtallo, M.S., R.Ph., BCNSP, FASHP, FASPEN"
    },
    {
      "type": "text",
      "section": "NUTRITION SUPPORT COMPLICATIONS: GLUCOSE CONTROL IN NUTRITION SUPPORT",
      "line": 16,
      "preview": "The Ohio State University ASPEN"
    },
    {
      "type": "text",
      "section": "NUTRITION SUPPORT COMPLICATIONS: GLUCOSE CONTROL IN NUTRITION SUPPORT",
      "line": 18,
      "preview": "NUTRITION SUPPORT CERTIFICATE"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 20
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 22,
      "preview": "The following persons in control of this activity's content have relevant financial relationships:"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 24,
      "preview": "- Jay Mirtallo: Fresenius Kabi, consultant"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 26,
      "preview": "All other persons in control of content do not have any relevant financial relationships with an ine"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 28,
      "preview": "As defined by the Standards of Integrity and Independence definition of ineligible company. All rele"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 30,
      "preview": "--- page 2 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "LEARNING OBJECTIVES",
      "line": 32
    },
    {
      "type": "text",
      "section": "LEARNING OBJECTIVES",
      "line": 34,
      "preview": "- Review the clinical algorithm for controlling hyperglycemia in patients receiving nutrition suppor"
    },
    {
      "type": "text",
      "section": "LEARNING OBJECTIVES",
      "line": 35,
      "preview": "- Design a treatment plan for patients with hyperglycemia."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "KEY ABBREVIATIONS",
      "line": 38
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 40,
      "preview": "- AA:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 41,
      "preview": "- Alb:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 42,
      "preview": "- Alk Phosph:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 43,
      "preview": "- Bili, T:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 44,
      "preview": "- BMI:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 45,
      "preview": "- BUN:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 46,
      "preview": "- CaGluc:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 47,
      "preview": "- Cal:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 48,
      "preview": "- $\\mathrm{CO}_{2}$ :"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 49,
      "preview": "- Cr:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 50,
      "preview": "amino acids"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 51,
      "preview": "albumin"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 52,
      "preview": "alkaline phosphatase"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 53,
      "preview": "total bilirubin"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 54,
      "preview": "body mass index"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 55,
      "preview": "blood urea nitrogen"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 56,
      "preview": "calcium gluconate"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 57,
      "preview": "calories"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 58,
      "preview": "carbon dioxide"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 59,
      "preview": "creatinine"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 61,
      "preview": "--- page 3 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 63
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 65,
      "preview": "- D/C:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 66,
      "preview": "- Dext:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 67,
      "preview": "- Gluc:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 68,
      "preview": "- \\%IBW:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 69,
      "preview": "- IBW:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 70,
      "preview": "- KCl :"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 71,
      "preview": "- $\\mathrm{KPO}_{4}$ :"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 72,
      "preview": "- Lbs:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 73,
      "preview": "- $\\mathrm{MgSO}_{4}$ :"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 74,
      "preview": "- NaCl :"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 75,
      "preview": "discontinue"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 76,
      "preview": "dextrose"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 77,
      "preview": "glucose"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 78,
      "preview": "percent ideal body weigh"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 79,
      "preview": "ideal body weight"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 80,
      "preview": "potassium chloride"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 81,
      "preview": "potassium phosphate"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 82,
      "preview": "pounds"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 83,
      "preview": "magnesium sulfate"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 84,
      "preview": "sodium chloride"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 87
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 89,
      "preview": "- NS:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 90,
      "preview": "- PN:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 91,
      "preview": "- Tg:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 92,
      "preview": "- WBC:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 93,
      "preview": "- Wt:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 94,
      "preview": "nutrition support"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 95,
      "preview": "parenteral nutrition"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 96,
      "preview": "triglycerides"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 97,
      "preview": "white blood cell"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 98,
      "preview": "weight"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS, CONT.",
      "line": 100,
      "preview": "--- page 4 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 102
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 104,
      "preview": "The desired target glucose for a patient receiving nutrition support is in the range of which of the"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 105,
      "preview": "A. $100-150 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 106,
      "preview": "B. $70-220 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 107,
      "preview": "C. $140-180 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 108,
      "preview": "D. $180-220 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT\\#2",
      "line": 110
    },
    {
      "type": "image",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 112,
      "content": "![img-1.jpeg](images/277aa86e5e886225.png)"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 114,
      "preview": "What is the ASPEN guideline recommendation for defining hypoglycemia?"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 115,
      "preview": "A. Rapid fall of blood glucose in excess of $50 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 116,
      "preview": "B. $<70 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 117,
      "preview": "C. $<100 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 118,
      "preview": "D. $<40 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 120,
      "preview": "--- page 5 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN",
      "line": 122
    },
    {
      "type": "image",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN",
      "line": 124,
      "content": "![img-2.jpeg](images/ce4ac1417c994a62.png)"
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN",
      "line": 126,
      "preview": "| Reference | Criteria | $\\mathrm{N}(%)$ | Comment | NSS |"
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN",
      "line": 127,
      "preview": "| :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN",
      "line": 128,
      "preview": "| Dodds etal. NCP <br> 2001 | @ least 1 value <br> $>200 \\mathrm{mg} / \\mathrm{dl}$ | 762 (28) | Onl"
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN",
      "line": 129,
      "preview": "| Weinsieret*al. <br> JPEN 1982 | $>300 \\mathrm{mg} / \\mathrm{dl}$ after <br> at least 48 hrs of <br"
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN",
      "line": 130,
      "preview": "| ChrisAnderson* et <br> al JPEN 1996 | As per Weinsier | 23 (22) <br> (41) <br> (39) | No effect of"
    },
    {
      "type": "text",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN",
      "line": 132,
      "preview": "*Same institution"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN, CONT.",
      "line": 134
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN, CONT.",
      "line": 136,
      "preview": "| Reference | Criteria | $\\mathrm{N}(\\%)$ | Comment | NSS |"
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN, CONT.",
      "line": 137,
      "preview": "| :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN, CONT.",
      "line": 138,
      "preview": "| Rosmarinetal, <br> NCP 1995 | $>200 \\mathrm{mg} / \\mathrm{dl}$ | $\\begin{aligned} & 0(0) \\\\ & 5(7)"
    },
    {
      "type": "table",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN, CONT.",
      "line": 139,
      "preview": "| Pleva et al, NCP 2009 | $>200 \\mathrm{mg} / \\mathrm{dl}$ <br> $>150 \\mathrm{mg} / \\mathrm{dl}$ | $"
    },
    {
      "type": "text",
      "section": "FREQUENCY OF HYPERGLYCEMIA IN PN, CONT.",
      "line": 141,
      "preview": "--- page 6 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SEVERITY OF HYPERGLYCEMIA IN PN",
      "line": 143
    },
    {
      "type": "text",
      "section": "SEVERITY OF HYPERGLYCEMIA IN PN",
      "line": 145,
      "preview": "- Stronger predictor of adverse outcomes than history of diabetes"
    },
    {
      "type": "text",
      "section": "SEVERITY OF HYPERGLYCEMIA IN PN",
      "line": 146,
      "preview": "- Majority of PN patients who become hyperglycemic are not diabetic"
    },
    {
      "type": "text",
      "section": "SEVERITY OF HYPERGLYCEMIA IN PN",
      "line": 147,
      "preview": "- Excluded from Rosmarin study"
    },
    {
      "type": "text",
      "section": "SEVERITY OF HYPERGLYCEMIA IN PN",
      "line": 148,
      "preview": "- $12 \\%$ of Pleva study population"
    },
    {
      "type": "text",
      "section": "SEVERITY OF HYPERGLYCEMIA IN PN",
      "line": 149,
      "preview": "- $27 \\%$ of Wah Cheung study population"
    },
    {
      "type": "text",
      "section": "SEVERITY OF HYPERGLYCEMIA IN PN",
      "line": 150,
      "preview": "- Evidence that hyperglycemia in itself is harmful."
    },
    {
      "type": "text",
      "section": "SEVERITY OF HYPERGLYCEMIA IN PN",
      "line": 152,
      "preview": "Cheung NW, et al. Diabetes Care. 2005; 28:2367-71"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 154
    },
    {
      "type": "text",
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 156,
      "preview": "Risk factors:"
    },
    {
      "type": "text",
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 158,
      "preview": "- Diabetes"
    },
    {
      "type": "text",
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 159,
      "preview": "- Pre-existing hyperglycemia"
    },
    {
      "type": "text",
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 160,
      "preview": "- Glucose $>140 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 161,
      "preview": "- Pancreatitis"
    },
    {
      "type": "text",
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 162,
      "preview": "- Corticosteroids"
    },
    {
      "type": "text",
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 163,
      "preview": "- Octreotide"
    },
    {
      "type": "text",
      "section": "APPROACH TO IDENTIFYING HYPERGLYCEMIA RISK",
      "line": 165,
      "preview": "--- page 7 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "GLUCOSE CONTROL ALGORITHM STEP 1",
      "line": 167
    },
    {
      "type": "image",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 1",
      "line": 169,
      "content": "![img-3.jpeg](images/f5f7037ddcd2b75c.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 171
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 173,
      "preview": "- Establish routine monitoring protocol for at risk patients"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 174,
      "preview": "- Consider whether patient had been on insulin before"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 175,
      "preview": "- What is the feasibility of point of care glucose?"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 176,
      "preview": "- Establish criteria for abnormality"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 177,
      "preview": "- When action will be taken"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 178,
      "preview": "- May be different from target"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 179,
      "preview": "- Is sliding scale insulin the best option for glucose control?"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 180,
      "preview": "- Adjust the target range based on continuous, intermittent or cyclic nutrient administration"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 1 ADJUSTMENT",
      "line": 182,
      "preview": "--- page 8 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 184
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 186,
      "preview": "- Identify and manage glucose from sources other than NS"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 187,
      "preview": "- Is the patient hyperglycemic while on sliding scale insulin?"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 188,
      "preview": "- If yes, then minimize"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 189,
      "preview": "- Dextrose in IV fluids"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 190,
      "preview": "- Medications premixed in dextrose"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 191,
      "preview": "- For PN: oral diet or tube feeding adequate then taper or D/C PN"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 192,
      "preview": "- For EN: determine quantity and quality of glucose"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 2",
      "line": 193,
      "preview": "- Ingestion (minimize simple or added sugars)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 196
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 198,
      "preview": "| Fluid | Sugars <br> Grams@1 cc | Sugars <br> Grams/L | Calories <br> Content/L |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 199,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 200,
      "preview": "| Bottled water | 0 | 0 | 0 |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 201,
      "preview": "| Milk, 2\\% | 13 | 55 | 220 |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 202,
      "preview": "| Sports drink | $14-29$ | $59-123$ | $236-492$ |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 203,
      "preview": "| Orange juice | 24 | 101 | 404 |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 204,
      "preview": "| Coffee | 0 | 0 | 0 |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 205,
      "preview": "| Dietsoda | 0 | 0 | 0 |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 206,
      "preview": "| Dextrose 5\\% in Water (D5W) |  | 50 | 170 |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 207,
      "preview": "| Dextrose 10\\% in Water (D10W) |  | 100 | 340 |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 208,
      "preview": "| Dextrose 15\\% in Water (D15W) |  | 150 | 510 |"
    },
    {
      "type": "table",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 209,
      "preview": "| Dextrose 25\\% in Water (D25W) |  | 250 | 850 |"
    },
    {
      "type": "text",
      "section": "CARBOHYDRATE CONTENT OF FLUIDS",
      "line": 211,
      "preview": "--- page 9 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ALGORITHM - STEP 2 ADJUSTMENT",
      "line": 213
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 2 ADJUSTMENT",
      "line": 215,
      "preview": "- Establish criteria for categorizing the condition as hyperglycemia"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 2 ADJUSTMENT",
      "line": 216,
      "preview": "- If significant carbohydrate from oral intake tolerated for PN patients"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 2 ADJUSTMENT",
      "line": 217,
      "preview": "- Decrease dextrose content of PN"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 2 ADJUSTMENT",
      "line": 218,
      "preview": "- Taper PN"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 2 ADJUSTMENT",
      "line": 219,
      "preview": "- Frequency of infusions"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 2 ADJUSTMENT",
      "line": 220,
      "preview": "- Volume of infusion"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 2 ADJUSTMENT",
      "line": 221,
      "preview": "- Caloric content if intravenous fluid volume is still needed"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "GLUCOSE CONTROL ALGORITHM STEP 3: ADDING INSULIN TO PN",
      "line": 224
    },
    {
      "type": "image",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 3: ADDING INSULIN TO PN",
      "line": 226,
      "content": "![img-4.jpeg](images/6cbd8f13034198f0.png)"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 3: ADDING INSULIN TO PN",
      "line": 228,
      "preview": "What is the patient's glucose level prior to initiation?"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 3: ADDING INSULIN TO PN",
      "line": 230,
      "preview": "Euglycemic (for diabetic): Insulin dose 0.1 U per gram of Dextrose ( 20 units for 200 grams)"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 3: ADDING INSULIN TO PN",
      "line": 232,
      "preview": "Serum glucose $>300 \\mathrm{mg} / \\mathrm{dl}$ :PN contraindicated. Normalize glucose prior to initi"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 3: ADDING INSULIN TO PN",
      "line": 234,
      "preview": "Glucose between $140-180 \\mathrm{mg} / \\mathrm{dL}$ Insulin dose: $0.1-0.2 \\mathrm{U}$ per gram of d"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 3: ADDING INSULIN TO PN",
      "line": 236,
      "preview": "Glucose $>180 \\mathrm{mg} / \\mathrm{dL}$ : initiate PN with no more than 100 g dextrose. Insulin dos"
    },
    {
      "type": "text",
      "section": "GLUCOSE CONTROL ALGORITHM STEP 3: ADDING INSULIN TO PN",
      "line": 238,
      "preview": "--- page 10 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ALGORITHM - STEP 3 ADJUSTMENT",
      "line": 240
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 3 ADJUSTMENT",
      "line": 242,
      "preview": "- For Diabetics: determine daily dose of insulin used on a daily basis while stable"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 3 ADJUSTMENT",
      "line": 243,
      "preview": "- This may be the basal needs of insulin for the patient and can be added to the PN or administered "
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 3 ADJUSTMENT",
      "line": 244,
      "preview": "- Consider criteria for withholding or discontinuing PN for hyper- or hypoglycemia"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 3 ADJUSTMENT",
      "line": 245,
      "preview": "- Taper insulin in PN if patient becomes hypoglycemic"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "GLUCOSE ALGORITHM - STEP 4",
      "line": 248
    },
    {
      "type": "image",
      "section": "GLUCOSE ALGORITHM - STEP 4",
      "line": 250,
      "content": "![img-5.jpeg](images/6cbd8f13034198f0.png)"
    },
    {
      "type": "image",
      "section": "GLUCOSE ALGORITHM - STEP 4",
      "line": 252,
      "content": "![img-6.jpeg](images/b5ad383a1d2e5fd1.png)"
    },
    {
      "type": "text",
      "section": "GLUCOSE ALGORITHM - STEP 4",
      "line": 254,
      "preview": "--- page 11 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 256
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 258,
      "preview": "- Point-of-care glucose for cycled PN"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 259,
      "preview": "- 2 hours into and 1 hour post PN infusion"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 260,
      "preview": "- Values dependent on glucose infusion rate"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 261,
      "preview": "- Laboratory values usually drawn when PN infusion or cycle is complete"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 262,
      "preview": "- Not as useful - establish false sense of security"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 263,
      "preview": "- Monitor for symptoms of hypoglycemia"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 264,
      "preview": "- No matter what the blood glucose is, this is a problem that must be addressed immediately"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 265,
      "preview": "- Weakness, sweating, palpitations, anxiety, irritability"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 266,
      "preview": "- Serious: seizures"
    },
    {
      "type": "text",
      "section": "ALGORITHM - STEP 4 ADJUSTMENT",
      "line": 267,
      "preview": "- Long term assessment: Hemoglobin A1c"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 270
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 272,
      "preview": "The desired target glucose for a patient receiving nutrition support is in the range of which of the"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 273,
      "preview": "A. $100-150 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 274,
      "preview": "B. $70-220 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 275,
      "preview": "C. $140-180 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 276,
      "preview": "D. $180-220 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 278,
      "preview": "--- page 12 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 280
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 282,
      "preview": "The desired target glucose for a patient receiving nutrition support is in the range of which of the"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 283,
      "preview": "A. $100-150 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 284,
      "preview": "B. $70-220 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 285,
      "preview": "C. $140-180 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 286,
      "preview": "D. $180-220 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT\\#2",
      "line": 288
    },
    {
      "type": "image",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 290,
      "content": "![img-7.jpeg](images/277aa86e5e886225.png)"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 292,
      "preview": "What is the ASPEN guideline recommendation for defining hypoglycemia?"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 293,
      "preview": "A. Rapid fall of blood glucose in excess of $50 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 294,
      "preview": "B. $<70 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 295,
      "preview": "C. $<100 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 296,
      "preview": "D. $<40 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT\\#2",
      "line": 298,
      "preview": "--- page 13 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#2",
      "line": 300
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 302,
      "preview": "What is the ASPEN guideline recommendation for defining hypoglycemia?"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 303,
      "preview": "A. Rapid fall of blood glucose in excess of $50 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 304,
      "preview": "B. $<70 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 305,
      "preview": "C. $<100 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 306,
      "preview": "D. $<40 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "ALGORITHM SUMMARY",
      "line": 308
    },
    {
      "type": "text",
      "section": "ALGORITHM SUMMARY",
      "line": 310,
      "preview": "- Glucose control in NS patients is critical to optimal patient outcomes"
    },
    {
      "type": "text",
      "section": "ALGORITHM SUMMARY",
      "line": 311,
      "preview": "- An effective approach to glucose control is to establish"
    },
    {
      "type": "text",
      "section": "ALGORITHM SUMMARY",
      "line": 312,
      "preview": "- Interdisciplinary process of care"
    },
    {
      "type": "text",
      "section": "ALGORITHM SUMMARY",
      "line": 313,
      "preview": "- Specific goals of therapy"
    },
    {
      "type": "text",
      "section": "ALGORITHM SUMMARY",
      "line": 314,
      "preview": "- A monitoring plan to identify and prevent serious problems from glucose control"
    },
    {
      "type": "text",
      "section": "ALGORITHM SUMMARY",
      "line": 315,
      "preview": "- Establish a consistent approach (algorithm) for patient management"
    },
    {
      "type": "text",
      "section": "ALGORITHM SUMMARY",
      "line": 317,
      "preview": "--- page 14 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "CASE STUDY: PATIENT MJ",
      "line": 319
    },
    {
      "type": "text",
      "section": "CASE STUDY: PATIENT MJ",
      "line": 321,
      "preview": "- A 35 year old male with a history of Colon Cancer status post multiple intestinal and colon resect"
    },
    {
      "type": "text",
      "section": "CASE STUDY: PATIENT MJ",
      "line": 322,
      "preview": "- Most recently, he had a drainage of an intra-abdominal abscess; a procedure that was complicated b"
    },
    {
      "type": "text",
      "section": "CASE STUDY: PATIENT MJ",
      "line": 323,
      "preview": "- He was started on PN 3 days ago and is currently receiving his goal calories and protein at a cont"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "NUTRITIONAL STATUS",
      "line": 326
    },
    {
      "type": "text",
      "section": "NUTRITIONAL STATUS",
      "line": 328,
      "preview": "- Ht: 5' 8\""
    },
    {
      "type": "text",
      "section": "NUTRITIONAL STATUS",
      "line": 329,
      "preview": "- Wt: 220 pounds"
    },
    {
      "type": "text",
      "section": "NUTRITIONAL STATUS",
      "line": 330,
      "preview": "- He is post-op day 4 and he is expected to be discharged to home on this his 10th day of hospitaliz"
    },
    {
      "type": "text",
      "section": "NUTRITIONAL STATUS",
      "line": 331,
      "preview": "- His nutritional intake in the hospital was minimal prior to the findings of the enterocutaneous fi"
    },
    {
      "type": "text",
      "section": "NUTRITIONAL STATUS",
      "line": 332,
      "preview": "- He has high fistula output (about 1 liter per day) and is allowed to drink Gatorade ${ }^{\\circled"
    },
    {
      "type": "text",
      "section": "NUTRITIONAL STATUS",
      "line": 334,
      "preview": "--- page 15 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "NUTRITION HISTORY",
      "line": 336
    },
    {
      "type": "table",
      "section": "NUTRITION HISTORY",
      "line": 338,
      "preview": "| Age: 35 | Assessment: No recent weight loss |"
    },
    {
      "type": "table",
      "section": "NUTRITION HISTORY",
      "line": 339,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "NUTRITION HISTORY",
      "line": 340,
      "preview": "| Admit Wt: 100kg | \\% IBW: 142 |"
    },
    {
      "type": "table",
      "section": "NUTRITION HISTORY",
      "line": 341,
      "preview": "| Ht: 5'8\" | BMI: 34 |"
    },
    {
      "type": "table",
      "section": "NUTRITION HISTORY",
      "line": 342,
      "preview": "| IBW: 70 | Usual body weight: 100 kg |"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "PN FORMULA",
      "line": 344
    },
    {
      "type": "image",
      "section": "PN FORMULA",
      "line": 346,
      "content": "![img-8.jpeg](images/f36f292952523fbf.png)"
    },
    {
      "type": "table",
      "section": "PN FORMULA",
      "line": 348,
      "preview": "| PN Volume: 3000 ml | Continuous Infusion: 125 mL/hour |  |  |  |"
    },
    {
      "type": "table",
      "section": "PN FORMULA",
      "line": 349,
      "preview": "| :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "PN FORMULA",
      "line": 350,
      "preview": "|  | Cal/day | Total Cal | Cal/kg | $\\begin{gathered} \\text { AA } \\\\ \\mathrm{g} / \\mathrm{kg} \\end{"
    },
    {
      "type": "table",
      "section": "PN FORMULA",
      "line": 351,
      "preview": "| Dextrose: 412 g | 1400 | 2800 | 28 | 1 |"
    },
    {
      "type": "table",
      "section": "PN FORMULA",
      "line": 352,
      "preview": "| AA: 100 g | 400 |  |  |  |"
    },
    {
      "type": "table",
      "section": "PN FORMULA",
      "line": 353,
      "preview": "| Fat: 100 g | 1000 |  |  |  |"
    },
    {
      "type": "text",
      "section": "PN FORMULA",
      "line": 355,
      "preview": "--- page 16 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PN ADDITIVES",
      "line": 357
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 359,
      "preview": "- Electrolytes per day"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 360,
      "preview": "- NaCl 200 mEq"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 361,
      "preview": "- $\\mathrm{KCl} 60 \\mathrm{mEq}$"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 362,
      "preview": "- $\\mathrm{KPO}_{4} 60 \\mathrm{mEq}(45 \\mathrm{mmol} / \\mathrm{d})$"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 363,
      "preview": "- CaGluc 10 mEq"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 364,
      "preview": "- $\\mathrm{MgSO}_{4} 16 \\mathrm{mEq}$"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 365,
      "preview": "- Trace Elements per day"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 366,
      "preview": "- Multitrace-4, 5 ml"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 367,
      "preview": "- Vitamins per day"
    },
    {
      "type": "text",
      "section": "PN ADDITIVES",
      "line": 368,
      "preview": "- Multivitamins, 10 ml"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "LAB VALUES",
      "line": 371
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 373,
      "preview": "| Date | Baseline | Day 1 | Today |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 374,
      "preview": "| :-- | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 375,
      "preview": "| WBC | 10 | 8 | 8.2 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 376,
      "preview": "| Hgb | 12.3 | 13 | 12.8 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 377,
      "preview": "| Na | 138 | 140 | 145 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 378,
      "preview": "| K | 4.0 | 3.7 | 4.1 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 379,
      "preview": "| Cl | 110 | 111 | 107 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 380,
      "preview": "| CO 2 | 21 | 24 | 26 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 381,
      "preview": "| Gluc | 185 | 224 | 280 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 382,
      "preview": "| BUN | 15 | 20 | 25 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES",
      "line": 383,
      "preview": "| Cr | 1.1 | 1.2 | 1.3 |"
    },
    {
      "type": "text",
      "section": "LAB VALUES",
      "line": 385,
      "preview": "--- page 17 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 387
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 389,
      "preview": "| Date | Baseline | Day 1 | Today |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 390,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 391,
      "preview": "| Bili, T | 1.5 |  | 1.2 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 392,
      "preview": "| Alk <br> Phosp | 65 |  | 154 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 393,
      "preview": "| Metabolic Parameters |  |  |  |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 394,
      "preview": "| Tg | 130 |  | 112 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 395,
      "preview": "| Alb | 2.0 | 1.8 |  |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 396,
      "preview": "| Ca | 7.6 | 7.8 | 9.8 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 397,
      "preview": "| Mg | 1.4 | 1.4 | 1.8 |"
    },
    {
      "type": "table",
      "section": "LAB VALUES: LIVER FUNCTION AND METABOLIC PARAMETERS",
      "line": 398,
      "preview": "| Phosp | 3.0 | 2.0 | 3.0 |"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#3",
      "line": 400
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 402,
      "preview": "What risk factors does this patient have for hyperglycemia while on PN?"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 403,
      "preview": "A. Pre-existing hyperglycemia"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 404,
      "preview": "B. Pancreatitis"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 405,
      "preview": "C. Corticosteroids"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 406,
      "preview": "D. Diabetes"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 407,
      "preview": "E. Octreotide"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 409,
      "preview": "--- page 18 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#3",
      "line": 411
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 413,
      "preview": "What risk factors does this patient have for hyperglycemia while on PN?"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 414,
      "preview": "A. Pre-existing hyperglycemia"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 415,
      "preview": "B. Pancreatitis"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 416,
      "preview": "C. Corticosteroids"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 417,
      "preview": "D. Diabetes"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 418,
      "preview": "E. Octreotide"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#4",
      "line": 420
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 422,
      "preview": "If you were to add insulin to his PN at this time, what dose would you start with?"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 423,
      "preview": "A. 15 units"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 424,
      "preview": "B. 20 units"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 425,
      "preview": "C. 40 units ( 0.1 U per gram dextrose)"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 426,
      "preview": "D. 50 units"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 428,
      "preview": "--- page 19 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#4",
      "line": 430
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 432,
      "preview": "If you were to add insulin to his PN at this time, what dose would you start with?"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 433,
      "preview": "A. 15 units"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 434,
      "preview": "B. 20 units"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 435,
      "preview": "C. 40 units ( 0.1 U per gram dextrose)"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#4",
      "line": 436,
      "preview": "D. 50 units"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#5",
      "line": 438
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 440,
      "preview": "Choose a target range for glucose in this patient:"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 441,
      "preview": "A. $80-120 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 442,
      "preview": "B. $100-150 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 443,
      "preview": "C. $140-180 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 444,
      "preview": "D. $150-200 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 446,
      "preview": "--- page 20 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#5",
      "line": 448
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 450,
      "preview": "Choose a target range for glucose in this patient:"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 451,
      "preview": "A. $80-120 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 452,
      "preview": "B. $100-150 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 453,
      "preview": "C. $140-180 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#5",
      "line": 454,
      "preview": "D. $150-200 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF ASSESSMENT \\#6",
      "line": 456
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 458,
      "preview": "What additional monitoring tools would you order for this patient to better assess glucose control?"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 459,
      "preview": "A. Urine for sugar and acetone"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 460,
      "preview": "B. Serum and urine Osmolality"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 461,
      "preview": "C. Capillary blood glucose every 12 hours"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 462,
      "preview": "D. Capillary blood glucose every 6 hours"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 464,
      "preview": "--- page 21 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF ASSESSMENT \\#6",
      "line": 466
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 468,
      "preview": "What additional monitoring tools would you order for this patient to better assess glucose control?"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 469,
      "preview": "A. Urine for sugar and acetone"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 470,
      "preview": "B. Serum and urine Osmolality"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 471,
      "preview": "C. Capillary blood glucose every 12 hours"
    },
    {
      "type": "text",
      "section": "SELF ASSESSMENT \\#6",
      "line": 472,
      "preview": "D. Capillary blood glucose every 6 hours"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "CONCLUSIONS",
      "line": 474
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 476,
      "preview": "- Glucose control in PN patients requires attention to a variety of details in order to keep the glu"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 477,
      "preview": "- The planned approach includes"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 478,
      "preview": "- Identifying risk factors for hyper- or hypoglycemia"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 479,
      "preview": "- Establish a target glucose range"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 480,
      "preview": "- Properly dose insulin when needed"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 481,
      "preview": "- Modify glucose monitoring when glucose is poorly controlled"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 483,
      "preview": "--- page 22 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "REFERENCES",
      "line": 485
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 487,
      "preview": "- Ahrens CL, Barietta JF, Kanji S et al. Effect of low-calorie parenteral nutrition on the incidence"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 488,
      "preview": "- Cheung NW, Zaccaria C, Napier B, Fletcher JP. Hyperglycemia is associated with adverse outcomes in"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 489,
      "preview": "- Choban PS, Burge JC, Scales D, Flancbaum L. Hypoenergetic nutrition support in hospitalized obese "
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 490,
      "preview": "- ChrisAnderson D, Heimburger DC, Morgan SL et al. Metabolic complications of total parenteral nutri"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "REFERENCES, CONT.",
      "line": 493
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 495,
      "preview": "- Dodds ES, Murray JD, Trexler KM, Grant JP. Metabolic occurrences in total parenteral nutrition pat"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 496,
      "preview": "- McCowen KC, Friel C, Sternberg J, et al. Hypocaloric total parenteral nutrition: effectiveness in "
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 497,
      "preview": "- McMahon MM, Nystrom E, Braunschweig C et al. A.S.P.E.N. Clinical Guidelines: Nutrition support of "
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 498,
      "preview": "- Mirtallo JM, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. J Parenteral Ent"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 500,
      "preview": "--- page 23 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "REFERENCES, CONT.",
      "line": 502
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 504,
      "preview": "- Mirtallo JM, Fabri PJ. Hemoglobin A1c in home parenteral nutrition. J Parenter Enter Nutr. 1983; 7"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 505,
      "preview": "- Pleva M, Mirtallo JM, Steinberg SM. Hyperglycemic events in nonintensive care unit patients receiv"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 506,
      "preview": "- Popkin BM, Armstrong LE, Bray GM, et al. A new proposed guidance system for beverage consumption i"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 507,
      "preview": "- Rosmarin DK, Wardlaw GM, Mirtallo J. Hyperglycemia associated with high, continuous infusion rates"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "REFERENCES, CONT.",
      "line": 510
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 512,
      "preview": "- Weinsier RL, Bacon J, Butterworth CE. Central venous alimentation: a prospective study of the freq"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 514,
      "preview": "--- page 24 ---"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 516,
      "preview": "NUTRITION SUPPORT CERTIFICATE"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 518,
      "preview": "--- page 25 ---"
    },
    {
      "type": "image",
      "section": "REFERENCES, CONT.",
      "line": 520,
      "content": "![img-9.jpeg](images/4d44f444ade286bb.png)"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 522,
      "preview": "Jay M. Mirtallo, M.S., R.Ph, BCNSP, FASHP, FASPEN"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 523,
      "preview": "The Professor Emeritus"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 524,
      "preview": "The Ohio State University, College of Pharmacy"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 525,
      "preview": "Clinical Practice Specialist"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 526,
      "preview": "American Society for Parenteral and Enteral Nutrition"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 527,
      "preview": "Delaware, Ohio"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 528,
      "preview": "As one of the pharmacy specialist pioneers, Professor Mirtallo was instrumental in leading cost-effe"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 530,
      "preview": "Professor Mirtallo has been very active in professional societies and is Past President of the Ameri"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 532,
      "preview": "As a representative to the Joint Commission, he served on the task force that created the Nutrition "
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 534,
      "preview": "--- page 26 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Relevant Financial Relationship Disclosure",
      "line": 536
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 538,
      "preview": "In accordance with our accreditor\u2019s Standards of Integrity and Independence in Accredited Continuing"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 540,
      "preview": "An ineligible company is any entity producing, marketing, re-selling, or distributing health care go"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 542,
      "preview": "The following persons in control of this activity\u2019s content have relevant financial relationships:"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 544,
      "preview": "- Phil Ayers: Fresenius Kabi, consultant and speaker"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 545,
      "preview": "- David Evans: Fresenius Kabi, consultant and speaker; Abbott Laboratories, consultant and speaker; "
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 546,
      "preview": "- Andrew Mays: Fresenius Kabi, speaker"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 547,
      "preview": "- Jay Mirtallo: Fresenius Kabi, consultant"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 548,
      "preview": "- Kris Mogensen: Baxter, speaker; ThriveRx, advisory board; Pfizer, advisory board"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 550,
      "preview": "All other persons in control of content do not have any relevant financial relationships with an ine"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 552,
      "preview": "As required by the Standards of Integrity and Independence in Accredited Continuing Education defini"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Methods and CE Requirements",
      "line": 554
    },
    {
      "type": "text",
      "section": "Methods and CE Requirements",
      "line": 556,
      "preview": "This online activity consists of a combined total of 12 learning modules. Pharmacists and physicians"
    },
    {
      "type": "text",
      "section": "Methods and CE Requirements",
      "line": 558,
      "preview": "Participants must participate in the entire activity, complete the evaluation and all required compo"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Important Note \u2013 ACPE 60 Day Deadline:",
      "line": 560
    },
    {
      "type": "text",
      "section": "Important Note \u2013 ACPE 60 Day Deadline:",
      "line": 562,
      "preview": "Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "System Technical Requirements",
      "line": 564
    },
    {
      "type": "text",
      "section": "System Technical Requirements",
      "line": 566,
      "preview": "Courses and learning activities are delivered via your Web browser and Acrobat PDF. Users should hav"
    },
    {
      "type": "text",
      "section": "System Technical Requirements",
      "line": 568,
      "preview": "View Frequently Asked Questions for more information."
    }
  ],
  "images": [
    {
      "sha_name": "9c01a79eee8ab186.png",
      "original_ref": "img-0.jpeg",
      "page": 1,
      "relative_path": "images/9c01a79eee8ab186.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/9c01a79eee8ab186.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "9c01a79eee8ab186"
    },
    {
      "sha_name": "277aa86e5e886225.png",
      "original_ref": "img-1.jpeg",
      "page": 4,
      "relative_path": "images/277aa86e5e886225.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/277aa86e5e886225.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "277aa86e5e886225"
    },
    {
      "sha_name": "ce4ac1417c994a62.png",
      "original_ref": "img-2.jpeg",
      "page": 5,
      "relative_path": "images/ce4ac1417c994a62.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/ce4ac1417c994a62.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "ce4ac1417c994a62"
    },
    {
      "sha_name": "f5f7037ddcd2b75c.png",
      "original_ref": "img-3.jpeg",
      "page": 7,
      "relative_path": "images/f5f7037ddcd2b75c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/f5f7037ddcd2b75c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f5f7037ddcd2b75c"
    },
    {
      "sha_name": "6cbd8f13034198f0.png",
      "original_ref": "img-4.jpeg",
      "page": 9,
      "relative_path": "images/6cbd8f13034198f0.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/6cbd8f13034198f0.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "6cbd8f13034198f0"
    },
    {
      "sha_name": "6cbd8f13034198f0.png",
      "original_ref": "img-5.jpeg",
      "page": 10,
      "relative_path": "images/6cbd8f13034198f0.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/6cbd8f13034198f0.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "6cbd8f13034198f0"
    },
    {
      "sha_name": "b5ad383a1d2e5fd1.png",
      "original_ref": "img-6.jpeg",
      "page": 10,
      "relative_path": "images/b5ad383a1d2e5fd1.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/b5ad383a1d2e5fd1.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "b5ad383a1d2e5fd1"
    },
    {
      "sha_name": "277aa86e5e886225.png",
      "original_ref": "img-7.jpeg",
      "page": 12,
      "relative_path": "images/277aa86e5e886225.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/277aa86e5e886225.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "277aa86e5e886225"
    },
    {
      "sha_name": "f36f292952523fbf.png",
      "original_ref": "img-8.jpeg",
      "page": 15,
      "relative_path": "images/f36f292952523fbf.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/f36f292952523fbf.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f36f292952523fbf"
    },
    {
      "sha_name": "4d44f444ade286bb.png",
      "original_ref": "img-9.jpeg",
      "page": 25,
      "relative_path": "images/4d44f444ade286bb.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8_GlucoseControl/images/4d44f444ade286bb.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "4d44f444ade286bb"
    }
  ],
  "extraction": {
    "ocr_model": "mistral-ocr-latest",
    "request_id": "local-1754696236",
    "ts": "2025-08-08T23:37:16.342256+00:00"
  }
}